Natalizumab: Parvovirus B19 infection and acute acalculous cholecystitis: case report.

Acute Acalculous Cholecystitis in a Multiple Sclerosis Patient Treated with Natalizumab. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 37-year-old woman developed parvovirus B19 (B19V) infection and acute acalculous cholecystitis (AAC) during treatment with natalizumab for relapsing-remitting multiple sclerosis (RR-MS) [ I time to reactions onsets not stated i ]. Her serologic tests including IgM and IgG antibodies tests were positive for B19V infection, which was considered as secondary to the immunosuppressive effect of the natalizumab therapy. [Extracted from the article]